Compare Edison International Common Stock (EIX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edison International Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Edison International Common Stock trades at $55.46 (market cap $21.35B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Edison International Common Stock is far larger — about 4.4× Travere Therapeutics Inc. Common Stock's market cap, and Edison International Common Stock pays a 6.33% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edison International Common Stock for 4 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EIX | TVTX | |
|---|---|---|
Market Cap | $21.35B | $4.88B |
Volume | 15,485,731 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $80.38 | $67.52 |
52-Week Low | $51.47 | $26.79 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $64.73B | $5.01B |
Dividend Yield | 6.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edison International (EIX) trades at $55.48, down 0.29% on the day, with a bullish technical signal despite mixed oscillators. The stock offers a high dividend yield of 6.4% and trades below the consensus price target of $59.29. Recent earnings have consistently beaten estimates, with Q3 2026 results pending. However, the stock faces headwinds from unresolved California wildfire liability risks, contributing to a 23% decline in late August 2026.
EIX presents a value opportunity with low P/E (5.73) and P/B (1.22) ratios, strong profitability (ROE 23.06%), and a stable dividend. Key risks include regulatory uncertainty around wildfire costs and a projected decline in 2026 net margin. Analyst sentiment is mixed but leans positive, with 40.5% buy ratings. The stock's upside depends on regulatory clarity and sustained earnings growth.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edison International Common Stock
Edison International is the parent company of Southern California Edison, an electric utility that supplies and delivers electricity across Southern California. It also owns Trio, an energy advisory business.
Read more on EIX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
